Growth Differentiation Factor 15 (GDF-15) in Patients Admitted for Acute Heart Failure: Results from the RELAX-AHF Study

Abstract

In AHF patients enrolled in the RELAX-AHF study, increases in GDF-15 levels, but not baseline measurements, were associated with a greater likelihood of adverse outcomes. Serelaxin administration was associated with greater decreases in GDF-15 compared with placebo.